Ubrogepant

證據等級: L5

預測適應症: 3 個

Ubrogepant: From Migraine to Migraine with Brainstem Aura

One-Sentence Summary

Ubrogepant is an oral CGRP (calcitonin gene-related peptide) receptor antagonist originally developed for the acute treatment of migraine with or without aura in adults. The TxGNN model predicts it may also be effective for Migraine with Brainstem Aura, a rare migraine subtype, with 0 dedicated clinical trials for this specific subtype but 20 supporting publications on ubrogepant’s pharmacology, safety, and efficacy in general migraine.

Quick Overview

Item	Content
Original Indication	Acute treatment of migraine (with/without aura) — established via literature (PMID 32020557); no formal license record in evidence pack
Predicted New Indication	Migraine with Brainstem Aura
TxGNN Prediction Score	99.85% (rank 4506)
Evidence Level	L3
US Market Status	✗ Not Marketed (per evidence pack; note: conflicts with literature indicating FDA approval as Ubrelvy in Dec 2019 — see Market Information section)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack (data gap DG002). Based on known information from the supporting literature, ubrogepant is a small-molecule, highly-selective CGRP receptor antagonist (“gepant”) that blocks calcitonin gene-related peptide-mediated activation of the trigeminovascular system, a key pathway in migraine pain transmission. Its efficacy in acute migraine treatment (with or without aura) has been established through Phase 3 RCTs (ACHIEVE I/II) and is FDA-approved in the United States.

Migraine with brainstem aura (formerly “basilar-type migraine”) is a rare migraine subtype involving brainstem-origin aura symptoms. Since ubrogepant’s mechanism does not involve vasoconstriction — unlike triptans, which are often contraindicated or used with caution in this subtype due to theoretical cerebrovascular risk — CGRP receptor blockade offers a mechanistically plausible, lower vasoconstrictive-risk alternative. However, this rationale is extrapolated from general migraine trial data; no Phase 3 or subtype-specific RCT currently exists for migraine with brainstem aura specifically, meaning the prediction rests on mechanistic plausibility rather than direct outcome evidence.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37979595	2023	RCT (Phase 3)	Lancet	Ubrogepant 100mg vs placebo for acute migraine treatment administered during the prodrome phase, before headache onset
31742631	2019	RCT	JAMA	ACHIEVE II trial: ubrogepant superior to placebo for pain freedom and relief of most bothersome associated symptom at 2 hours
33874756	2021	RCT (subgroup analysis)	Cephalalgia	Safety and efficacy of ubrogepant across cardiovascular risk categories in ACHIEVE I/II — no vasoconstrictive safety signal
39569702	2025	RCT (safety/DDI substudy)	Headache	TANDEM study: safety/tolerability of ubrogepant for acute treatment in patients on concurrent preventive atogepant
31913519	2020	RCT (52-week extension)	Headache	Long-term safety of ubrogepant over 52 weeks of repeated acute treatment
32020557	2020	Review	Drugs	First global approval summary: ubrogepant approved in the US (Dec 2019) for acute migraine treatment ± aura
32011192	2020	Review	Expert Opin Pharmacother	Overview of CGRP-mediated neurogenic inflammation and trigeminovascular pathway relevant to ubrogepant’s mechanism
35790906	2022	Network Meta-analysis	J Headache Pain	Comparative efficacy of ubrogepant vs. lasmiditan and rimegepant for acute migraine treatment
38307667	2024	Review	Handbook Clin Neurol	Overview of second-generation gepants (ubrogepant, rimegepant) and CGRP-mediated antimigraine mechanism
33948091	2021	Narrative Review	J Pain Res	Summary of ACHIEVE I/II trial results and long-term open-label extension safety data

US Market Information

No license or NDA records are currently available in the evidence pack (taiwan_regulatory.total_licenses = 0). This is notable because the supporting literature (PMID 32020557) documents that ubrogepant (brand name Ubrelvy) received its first global FDA approval in December 2019 for acute migraine treatment in adults. This discrepancy suggests the market/license dataset in this evidence pack may be stale or incomplete and should be independently verified against current FDA Orange Book / TFDA records before proceeding.

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA label warnings/contraindications (DG001) constitute a blocking data gap — safety evaluation (Stage S1) cannot proceed until this is resolved.

Conclusion and Next Steps

Decision: Hold

Rationale: While the CGRP receptor antagonism mechanism is plausible for extending ubrogepant’s use from general migraine to the brainstem aura subtype, no direct clinical trial or case-level evidence exists for this specific indication, and a blocking data gap (missing TFDA/FDA label warnings and contraindications) prevents safety evaluation from proceeding to Stage S1.

To proceed, the following is needed:

TFDA/FDA package insert data — warnings, contraindications (DG001, blocking)
Confirmed mechanism of action detail from DrugBank (DG002)
Verification of actual current US/Taiwan market and license status (data conflict identified above)
Subtype-specific clinical evidence (case series or trial) for migraine with brainstem aura, given historical caution around vasoactive drugs in this population

Note: The two lower-ranked candidates (atrophoderma vermiculata, ulerythema ophryogenesis) show no mechanistic plausibility or supporting literature and are classified L5/Hold — likely knowledge-graph false positives, not recommended for further evaluation.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.